Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €67.66 EUR
Change Today +0.14 / 0.21%
Volume 326.0
LLY On Other Exchanges
Symbol
Exchange
New York
Mexico
SIX Swiss Ex
Sao Paulo
EN Paris
Frankfurt
As of 2:29 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

eli lilly & co (LLY) Snapshot

Open
€67.52
Previous Close
€67.52
Day High
€67.81
Day Low
€67.47
52 Week High
03/23/15 - €70.86
52 Week Low
04/8/14 - €40.00
Market Cap
75.2B
Average Volume 10 Days
1.5K
EPS TTM
--
Shares Outstanding
1.1B
EX-Date
02/11/15
P/E TM
--
Dividend
€1.93
Dividend Yield
2.31%
Current Stock Chart for ELI LILLY & CO (LLY)

eli lilly & co (LLY) Details

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health products. The company offers endocrinology products to treat diabetes; osteoporosis in postmenopausal women and men; human growth hormone deficiency and pediatric growth conditions; and testosterone deficiency. It also provides neuroscience products for the treatment of major depressive disorders, diabetic peripheral neuropathic pain, anxiety disorders, fibromyalgia, and chronic musculoskeletal pain; schizophrenia; attention-deficit hyperactivity disorders; depressive, obsessive-compulsive, bulimia nervosa, and panic disorders; and positron emission tomography imaging of beta-amyloid neurotic plaques in adult brains. In addition, the company offers products for the treatment of non-small cell lung, colorectal, head and neck, pancreatic, metastatic breast, ovarian, bladder, and metastatic gastric cancers, as well as malignant pleural mesothelioma; and cardiovascular products for the treatment of erectile dysfunction and benign prostatic hyperplasia, thrombotic cardiovascular events, and cardiac ischemic complications. Further, it provides animal health products, such as cattle feed additives; protein supplements for cows; leanness and performance enhancers for swine, cattle, and poultry; antibiotics to treat respiratory and other diseases in cattle, swine, and poultry; anticoccidial agents for poultry; and chewable tablets that kill fleas and prevent flea infestations, heartworm diseases, roundworm diseases, hookworm diseases, and whipworm diseases, as well as controls intestinal parasite infections in dogs. Additionally, the company offers products to treat chronic manifestations of atopic dermatitis and congestive heart failure in dogs; chronic allergic dermatitis and kidney diseases in cats. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

39,135 Employees
Last Reported Date: 02/19/15
Founded in 1876

eli lilly & co (LLY) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $1.0M
Executive Vice President of Science & Technol...
Total Annual Compensation: $1.0M
Senior Vice President and President of Lilly ...
Total Annual Compensation: $682.9K
General Counsel and Senior Vice President
Total Annual Compensation: $765.0K
Compensation as of Fiscal Year 2014.

eli lilly & co (LLY) Key Developments

Eli Lilly & Co. Wins £220.9 Million Multiple Awardees Contract for Supplying Proprietary Pharmaceuticals

Eli Lilly & Co. Ltd. won a £220.9 million (excluding VAT) multiple awardees contract award from The Secretary of State for Health acting as part of the Crown through the Commercial Medicines Unit (part of the Department of Health) for the supply of proprietary pharmaceuticals (Contract Award Notice No.: 2015/S 057-099494).

Eli Lilly and Company Collaborates with Innovent Biologics to Develop Possible New Treatment Options for Cancer Patients

Eli Lilly and Company, has collaborated with Innovent Biologics. It was reported that the firms have collaborated to develop possible new treatment options for cancer patients in China and around the world. Under the deal, both the companies will support the development and potential commercialisation of at least three cancer treatments over the next decade. In addition to the co-promotion rights, Innovent will be responsible for the development and manufacturing for the China market, while Lilly will commercialise the three potential medicines. The transaction will see Lilly contribute its cMet monoclonal antibody gene for possible treatment of non-small cell lung cancer, while Innovent will contribute its monoclonal antibody targeting protein CD-20 for investigation in hematologic malignancies. Both the companies have also agreed that Lilly will be responsible for development, manufacturing and commercialization of this molecule outside of China. Under the contract, Lilly will also receive rights to develop and commercialise up to three pre-clinical bispecific immuno-oncology molecules outside of China.

Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company Announce Availability of First-In-Class Type 2 Diabetes Treatment Glyxambi (Empagliflozin/Linagliptin) Tablets for Adults in U.S. Pharmacies

Glyxambi (empagliflozin/linagliptin) tablets are now available by prescription in many chain and independent pharmacies across the U.S., including Walgreens and Rite Aid. GLYXAMBI, part of the Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company. Diabetes alliance portfolio, is the first and only dual inhibitor combination therapy approved in the U.S. to combine the mechanisms of action of a sodium glucose co-transporter-2 (SGLT2) inhibitor and a dipeptidyl peptidase-4 (DPP-4) inhibitor in a once-daily tablet. GLYXAMBI is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) when both empagliflozin and linagliptin are appropriate treatments. GLYXAMBI is a once-daily tablet taken in the morning that combines 10 mg or 25 mg of empagliflozin, an SGLT2 inhibitor, with 5 mg of linagliptin, a DPP-4 inhibitor. GLYXAMBI is not for people with type 1 diabetes or for diabetic ketoacidosis (increased ketones in the blood or urine).

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LLY:GR €67.66 EUR +0.14

LLY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Amgen Inc $162.59 USD +2.04
AstraZeneca PLC 4,686 GBp -5.00
Baxter International Inc $68.55 USD +0.53
Bristol-Myers Squibb Co $65.26 USD +0.26
Novo Nordisk A/S kr369.70 DKK +34.70
View Industry Companies
 

Industry Analysis

LLY

Industry Average

Valuation LLY Industry Range
Price/Earnings 33.0x
Price/Sales 4.0x
Price/Book 5.1x
Price/Cash Flow 34.1x
TEV/Sales 3.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELI LILLY & CO, please visit www.lilly.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.